Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Brouwers

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
International Journal of Cardiology|October 28, 2017
Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general populationNavin Suthahar, Wouter C Meijers, Frank P Brouwers, et al.
The American Journal of Clinical Nutrition|March 18, 2016
Urinary potassium excretion and risk of cardiovascular eventsLyanne M Kieneker, Ron T Gansevoort, Rudolf A de Boer, et al.
Pediatrics|September 2, 1999
Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study TeamC Raskino, D A Pearson, C J Baker, et al.
Pediatrics|November 1, 1994
Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infectionB U Mueller, K M Butler, V L Stocker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphomaV Sandor, V Stark-Vancs, D Pearson, et al.
Clinical Cardiology|October 30, 2021
Proenkephalin and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage diseaseJohanna E Emmens, Jozine M Ter Maaten, Frank P Brouwers, et al.
European Heart Journal|March 9, 2013
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVENDFrank P Brouwers, Rudolf A de Boer, Pim van der Harst, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|May 9, 2025
Heart rhythm management optimisation of pacemaker recipients using remote monitoring: the HERO registryFleur W Adriaansen, Jaap Seelig, Tim A C de Vries, et al.
Journal of the American Heart Association|July 25, 2022
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND StudyS Heleen Binnenmars, Georgette E Hoogslag, Stanley M H Yeung, et al.
The Journal of Infectious Diseases|July 1, 1996
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working GroupL L Lewis, D Venzon, J Church, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
International Journal of Cardiology|October 28, 2017
Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general populationNavin Suthahar, Wouter C Meijers, Frank P Brouwers, et al.
The American Journal of Clinical Nutrition|March 18, 2016
Urinary potassium excretion and risk of cardiovascular eventsLyanne M Kieneker, Ron T Gansevoort, Rudolf A de Boer, et al.
Pediatrics|September 2, 1999
Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study TeamC Raskino, D A Pearson, C J Baker, et al.
Pediatrics|November 1, 1994
Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infectionB U Mueller, K M Butler, V L Stocker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphomaV Sandor, V Stark-Vancs, D Pearson, et al.
Clinical Cardiology|October 30, 2021
Proenkephalin and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage diseaseJohanna E Emmens, Jozine M Ter Maaten, Frank P Brouwers, et al.
European Heart Journal|March 9, 2013
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVENDFrank P Brouwers, Rudolf A de Boer, Pim van der Harst, et al.
Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|May 9, 2025
Heart rhythm management optimisation of pacemaker recipients using remote monitoring: the HERO registryFleur W Adriaansen, Jaap Seelig, Tim A C de Vries, et al.
Journal of the American Heart Association|July 25, 2022
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND StudyS Heleen Binnenmars, Georgette E Hoogslag, Stanley M H Yeung, et al.
The Journal of Infectious Diseases|July 1, 1996
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working GroupL L Lewis, D Venzon, J Church, et al.
Pageof 11